Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE: NVO) for violations of §§10 (b ...
The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback